ArticleHIV medicine2022

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).

Jennifer A Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.